Artwork

Content provided by Talking About Tumors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Talking About Tumors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

04_08 Metastatic Renal Cell Carcinoma

24:16
 
Share
 

Manage episode 432118872 series 3335024
Content provided by Talking About Tumors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Talking About Tumors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

1. Historical Approach (cytoreduction, IFN-a, sunitinib
2. Prognostic risk scores
3. Evidence for modern doublet regimens
4. Later line therapy

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. Flanigan RC et al. J Urol. 2004;171(3):1071-6. doi:10.1097/01.ju0000110610.61545.ae
  2. Bex A et al. JAMA Oncology. 2019;5(2):164-170. doi:10.1001/jamaoncol.2018.5545
  3. Mejean A et al. NEJM. 2018;379:417-427. doi:10.1056/NEJMoa1803675
  4. Motzer RJ et al. NEJM. 2007;356:115-124. doi:10.1056/NEJMoa065044
  5. Rini BI et al. NEJM. 2019;380:1116-1127. doi:10.1056/NEJMoa1816714
  6. Rini BI et al. JCO. 2023;41(17 Supp). doi:10.1200/JCO.2023.41.17_suppl.LBA4501
  7. Kartolo et al. Urology. 2021;157:8-14. doi:10.1016/j.urology.2021.08.023
  8. Motzer RJ et al. NEJM. 2018;378:1277-1290. doi:10.1056/NEJMoa1712126
  9. Motzer R et al. NEJM. 2021;384:1289-1300. doi:10.1056/NEJMoa2035716
  10. Albiges L et al. Ann Oncol. 2023;34(2 Supp):S1329-S1330. doi:10.1016/j.annonc.2023.10.090
  11. Jonasch E. ASCO Annual Meeting presented May 31, 2024 in Chicago, IL

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

47 episodes

Artwork
iconShare
 
Manage episode 432118872 series 3335024
Content provided by Talking About Tumors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Talking About Tumors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

1. Historical Approach (cytoreduction, IFN-a, sunitinib
2. Prognostic risk scores
3. Evidence for modern doublet regimens
4. Later line therapy

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. Flanigan RC et al. J Urol. 2004;171(3):1071-6. doi:10.1097/01.ju0000110610.61545.ae
  2. Bex A et al. JAMA Oncology. 2019;5(2):164-170. doi:10.1001/jamaoncol.2018.5545
  3. Mejean A et al. NEJM. 2018;379:417-427. doi:10.1056/NEJMoa1803675
  4. Motzer RJ et al. NEJM. 2007;356:115-124. doi:10.1056/NEJMoa065044
  5. Rini BI et al. NEJM. 2019;380:1116-1127. doi:10.1056/NEJMoa1816714
  6. Rini BI et al. JCO. 2023;41(17 Supp). doi:10.1200/JCO.2023.41.17_suppl.LBA4501
  7. Kartolo et al. Urology. 2021;157:8-14. doi:10.1016/j.urology.2021.08.023
  8. Motzer RJ et al. NEJM. 2018;378:1277-1290. doi:10.1056/NEJMoa1712126
  9. Motzer R et al. NEJM. 2021;384:1289-1300. doi:10.1056/NEJMoa2035716
  10. Albiges L et al. Ann Oncol. 2023;34(2 Supp):S1329-S1330. doi:10.1016/j.annonc.2023.10.090
  11. Jonasch E. ASCO Annual Meeting presented May 31, 2024 in Chicago, IL

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

47 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide